艾司美拉唑治疗胃溃疡患者成本效果的影响因素分析

被引：5

作者：

孙琪瑛 ^{[1
]}

王丹丹 ^{[2
]}

王轶 ^{[3
]}

李亚菊 ^{[4
]}

毛奇琦 ^{[5
]}

机构：

[1] 复旦大学附属华山医院北院财务资产管理部

[2] 复旦大学附属华山医院北院财务科

[3] 复旦大学附属华山医院北院药剂科

[4] 复旦大学附属华山医院北院检验科

[5] 复旦大学附属华山医院北院消化科

来源：

现代生物医学进展 | 2018年 / 18卷 / 24期

关键词：

艾司美拉唑; 胃溃疡; 成本效果; 不良反应; 影响因素;

D O I：

10.13241/j.cnki.pmb.2018.24.010

中图分类号：

R573.1 [溃疡病];

学科分类号：

100201 [内科学];

摘要：

目的:分析艾司美拉唑治疗胃溃疡患者成本效果的影响因素。方法:回顾性分析2014年9月-2018年1月我院诊治的胃溃疡患者220例的临床病例资料,根据治疗药物的不同分为观察组120例与对照组100例,对照组给予奥美拉唑+克拉霉素+阿莫西林治疗,观察组给予艾司美拉唑+克拉霉素+阿莫西林,两组均持续治疗观察2周,对比两组治疗成本、治疗效果、不良反应的发生情况和成本效果,以及影响艾司美拉唑治疗胃溃疡患者成本效果的因素。结果:观察组与对照组患者完成治疗周期的成本费用分别为567.14±48.23元、551.49±45.61元,两组比较差异无统计学意义(P>0.05)。观察组与对照组的治疗总有效率分别为95.83%(115/120)和82.00%(82/100),观察组显著高于对照组(P<0.05)。观察组与对照组治疗期间的腹胀、便秘、恶心、口腔异味等不良反应发生率为8.33%(10/120)和11.00%(11/100),对比差异无统计学意义(P>0.05)。观察组C/E与ΔC/E值均显著低于对照组(P<0.05)。多因素logistic回归分析显示病程、溃疡直径、不良反应为影响艾司美拉唑治疗胃溃疡成本效果的主要因素(P<0.05)。结论:艾司美拉唑治疗胃溃疡患者成本效果好,且不会增加不良反应的发生,病程、溃疡直径、不良反应为影响成本效果的主要因素。

引用

页码：4652 / 4655

页数：4

共 8 条

[1]

Effects of hydrotalcite combined with esomeprazole on gastric ulcer healing quality: A clinical observation study [J].

Yang, Rui-Qi ;

Mao, Hua ;

Huang, Li-Yun ;

Su, Pei-Zhu ;

Lu, Min .

WORLD JOURNAL OF GASTROENTEROLOGY, 2017, 23 (07) :1268-1277

[2]

Randomised clinical trial: gastrointestinal events in arthritis patients treated with celecoxib, ibuprofen or naproxen in the PRECISION trial [J].

Yeomans, N. D. ;

Graham, D. Y. ;

Husni, M. E. ;

Solomon, D. H. ;

Stevens, T. ;

Vargo, J. ;

Wang, Q. ;

Wisniewski, L. M. ;

Wolski, K. E. ;

Borer, J. S. ;

Libby, P. ;

Lincoff, A. M. ;

Luscher, T. F. ;

Bao, W. ;

Walker, C. ;

Nissen, S. E. .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2018, 47 (11) :1453-1463

[3]

A reduced esophageal epithelial integrity in a subgroup of healthy individuals increases with proton pump inhibitor therapy [J].

Pauwels, Ans ;

Broers, Charlotte ;

Vanuytsel, Tim ;

Pardon, Nicolas ;

Cocca, Silvia ;

Roman, Sabine ;

Zerbib, Frank ;

Tack, Jan ;

Farre, Ricard .

UNITED EUROPEAN GASTROENTEROLOGY JOURNAL, 2018, 6 (04) :511-518

[4]

Mo1194 - Natural History of Gastric Ulcer in a 25 Years Follow-Up: Role of Helicobacter Pylori Infection and Nonsteroidal Anti-Inflammatory Drugs.[J].Francesco Di Mario;Chiara Miraglia;Ottavia Cavatorta;Alberto Barchi;Mario Capasso;Lorella Franzoni;Pellegrino Crafa;Nadia Dal Bo';Renato Cannizzaro;Giuseppe Grande;Giovanni Brandimarte;Antonio Tursi;Carmelo Scarpignato;Massimo Rugge.Gastroenterology.2018, 6S1

[5]

Amaranth oil reduces accumulation of 4-hydroxynonenal-histidine adducts in gastric mucosa and improves heart rate variability in duodenal peptic ulcer patients undergoing Helicobacter pylori eradication [J].

Cherkas, Andriy ;

Zarkovic, Kamelija ;

Gasparovic, Ana Cipak ;

Jaganjac, Morana ;

Milkovic, Lidija ;

Abrahamovych, Orest ;

Yatskevych, Ostap ;

Waeg, Georg ;

Yelisyeyeva, Olha ;

Zarkovi, Neven .

FREE RADICAL RESEARCH, 2018, 52 (02) :135-149

[6]

Protective role of β-patchoulene from Pogostemon cablin against indomethacin-induced gastric ulcer in rats: Involvement of anti-inflammation and angiogenesis.[J].Jia-Zhen Wu;Yu-Hong Liu;Jia-Li Liang;Qiong-Hui Huang;Yao-Xing Dou;Juan Nie;Jian-Yi Zhuo;Xue Wu;Jian-Nan Chen;Zi-Ren Su;Qi-Duan Wu.Phytomedicine.2018,

[7]

Enhanced gastric stability of esomeprazole by molecular interaction and modulation of microenvironmental pH with alkalizers in solid dispersion [J].

Nguyen, Hien Van ;

Baek, Namhyun ;

Lee, Beom-Jin .

INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2017, 523 (01) :189-202

[8]

15-PGDH Inhibitors Promote Healing of Gastric Ulcer in Indomethacin Induced Mouse Model.[J].Sung Yeun Yang;Jin Hee Park;Kyung Han Nam;SaeGwang Park.Gastroenterology.2017, 5S1

← 1 →